Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Clinical Characteristics and Treatment Outcomes of Lung Adenocarcinomas with Discrepant EGFR Mutation Testing Results Derived from PCR-Direct Sequencing and Real-Time PCR-Based Assays

Clinical Characteristics and Treatment Outcomes of Lung Adenocarcinomas with Discrepant EGFR... ORIGINAL ARTICLE Clinical Characteristics and Treatment Outcomes of Lung  Adenocarcinomas with Discrepant EGFR Mutation Testing  Results Derived from PCR-Direct Sequencing and Real-Time  PCR-Based Assays Chao-Hua Chiu, MD,*†‡ Hsiang-Ling Ho, PhD,§ Chi-Lu Chiang, MD,‡ Shiou-Fu Lin, MD,║ Hsiu-Hsun Ma, MS,§ Yu-Ting Chuang, MS,§ Kun-Yang Lin, MS,§ Chun-Ming Tsai, MD,†‡ and Teh-Ying Chou, MD, PhD*§ Conclusions: DS overlooked EGFR mutation in a significant number Introduction: Detection of epidermal growth factor receptor (EGFR) of lung adenocarcinoma patients. These patients could have obtained mutation has become the most critical molecular test in managing the same benefit from EGFR-TKI when a high-sensitivity method patients with advanced lung adenocarcinoma. Whether patients with such as Scorpion/ARMS was applied. discrepant EGFR mutation results determined by low- and high-sen- sitivity methods have different clinical outcomes with EGFR tyrosine Key Words: Lung adenocarcinoma, Epidermal growth factor recep- kinase inhibitor (TKI) treatment needs to be further evaluated. tor, Mutation, Tyrosine kinase inhibitor. Methods: Genomic DNA from serial lung adenocarcinoma samples (J Thorac Oncol. 2014;9: 91–96) that were EGFR wild-type determined by direct sequencing (DS) were reanalyzed using Scorpion/Amplification Refractory Mutation System (ARMS). The outcomes with EGFR-TKI treatment among pidermal growth factor receptor (EGFR), a transmem- patients with discrepant EGFR mutation results between DS and Ebrane receptor tyrosine kinase, is frequently overexpressed Scorpion/ARMS versus patients with EGFR mutations detected http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Clinical Characteristics and Treatment Outcomes of Lung Adenocarcinomas with Discrepant EGFR Mutation Testing Results Derived from PCR-Direct Sequencing and Real-Time PCR-Based Assays

Journal of Thoracic Oncology , Volume 9 (1) – Jan 1, 2014

Loading next page...
 
/lp/wolters-kluwer-health/clinical-characteristics-and-treatment-outcomes-of-lung-28eJP51rLa

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Copyright
Copyright © 2013 by the International Association for the Study of Lung Cancer
ISSN
1556-0864
DOI
10.1097/JTO.0000000000000041
pmid
24346097
Publisher site
See Article on Publisher Site

Abstract

ORIGINAL ARTICLE Clinical Characteristics and Treatment Outcomes of Lung  Adenocarcinomas with Discrepant EGFR Mutation Testing  Results Derived from PCR-Direct Sequencing and Real-Time  PCR-Based Assays Chao-Hua Chiu, MD,*†‡ Hsiang-Ling Ho, PhD,§ Chi-Lu Chiang, MD,‡ Shiou-Fu Lin, MD,║ Hsiu-Hsun Ma, MS,§ Yu-Ting Chuang, MS,§ Kun-Yang Lin, MS,§ Chun-Ming Tsai, MD,†‡ and Teh-Ying Chou, MD, PhD*§ Conclusions: DS overlooked EGFR mutation in a significant number Introduction: Detection of epidermal growth factor receptor (EGFR) of lung adenocarcinoma patients. These patients could have obtained mutation has become the most critical molecular test in managing the same benefit from EGFR-TKI when a high-sensitivity method patients with advanced lung adenocarcinoma. Whether patients with such as Scorpion/ARMS was applied. discrepant EGFR mutation results determined by low- and high-sen- sitivity methods have different clinical outcomes with EGFR tyrosine Key Words: Lung adenocarcinoma, Epidermal growth factor recep- kinase inhibitor (TKI) treatment needs to be further evaluated. tor, Mutation, Tyrosine kinase inhibitor. Methods: Genomic DNA from serial lung adenocarcinoma samples (J Thorac Oncol. 2014;9: 91–96) that were EGFR wild-type determined by direct sequencing (DS) were reanalyzed using Scorpion/Amplification Refractory Mutation System (ARMS). The outcomes with EGFR-TKI treatment among pidermal growth factor receptor (EGFR), a transmem- patients with discrepant EGFR mutation results between DS and Ebrane receptor tyrosine kinase, is frequently overexpressed Scorpion/ARMS versus patients with EGFR mutations detected

Journal

Journal of Thoracic OncologyWolters Kluwer Health

Published: Jan 1, 2014

References